| Literature DB >> 19061830 |
Abstract
The role of the von Hippel-Lindau tumor suppressor protein (pVHL) in kidney cancer has provided a rationale for treating this disease with hypoxia-inducible factor (HIF) antagonists. In this issue, Simon and coworkers show that the molecular signature of VHL(-/-) kidney cancers is profoundly influenced by whether they produce both HIF2alpha and HIF1alpha or HIF2alpha alone.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19061830 DOI： 10.1016/j.ccr.2008.11.005
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743